Stock Analysts’ updated eps estimates for Friday, March 21st:
Adicet Bio (NASDAQ:ACET) had its buy rating reissued by analysts at Guggenheim. Guggenheim currently has a $7.00 target price on the stock.
agilon health (NYSE:AGL) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $320.00 price target on the stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its outperform rating reissued by analysts at William Blair.
Allurion Technologies (NYSE:ALUR) had its buy rating reaffirmed by analysts at Roth Mkm. The firm currently has a $16.00 price target on the stock.
Allurion Technologies (NYSE:ALUR) had its neutral rating reiterated by analysts at Chardan Capital. Chardan Capital currently has a $2.50 price target on the stock.
Altus Power (NYSE:AMPS) had its neutral rating reissued by analysts at Roth Mkm. They currently have a $5.00 target price on the stock.
Amprius Technologies (NYSE:AMPX) had its buy rating reissued by analysts at Roth Mkm. They currently have a $6.00 price target on the stock.
Amprius Technologies (NYSE:AMPX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $10.00 price target on the stock.
Alto Neuroscience (NYSE:ANRO) had its outperform rating reaffirmed by analysts at William Blair.
AtriCure (NASDAQ:ATRC) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $51.00 target price on the stock.
Beacon Roofing Supply (NASDAQ:BECN) had its hold rating reissued by analysts at Loop Capital. They currently have a $124.00 price target on the stock.
Barinthus Biotherapeutics (NASDAQ:BRNS) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $3.00 price target on the stock.
Cibus (NASDAQ:CBUS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $25.00 price target on the stock.
Context Therapeutics (NASDAQ:CNTX) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $5.00 price target on the stock.
Context Therapeutics (NASDAQ:CNTX) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $9.00 price target on the stock.
DHI Group (NYSE:DHX) had its outperform rating reiterated by analysts at Barrington Research. The firm currently has a $7.00 target price on the stock.
Emergent BioSolutions (NYSE:EBS) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $15.00 target price on the stock.
Erasca (NASDAQ:ERAS) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $6.00 price target on the stock.
Eyenovia (NASDAQ:EYEN) had its neutral rating reissued by analysts at HC Wainwright. The firm currently has a $2.00 price target on the stock.
Franklin Covey (NYSE:FC) had its outperform rating reiterated by analysts at Barrington Research. They currently have a $45.00 target price on the stock.
The GEO Group (NYSE:GEO) had its buy rating reiterated by analysts at Jones Trading. Jones Trading currently has a $55.00 target price on the stock.
IAC (NASDAQ:IAC) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. They currently have a $60.00 target price on the stock.
Intellicheck (NYSE:IDN) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $4.00 price target on the stock.
InflaRx (NASDAQ:IFRX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $8.00 price target on the stock.
Immuneering (NASDAQ:IMRX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $12.00 price target on the stock.
Longeveron (NASDAQ:LGVN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $10.00 price target on the stock.
Monolithic Power Systems (NASDAQ:MPWR) had its outperform rating reaffirmed by analysts at Oppenheimer Holdings Inc.. Oppenheimer Holdings Inc. currently has a $800.00 target price on the stock.
MetaVia (NASDAQ:MTVA) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $12.00 price target on the stock.
Micron Technology (NASDAQ:MU) had its overweight rating reiterated by analysts at Cantor Fitzgerald. They currently have a $130.00 target price on the stock.
OptiNose (NASDAQ:OPTN) had its neutral rating reaffirmed by analysts at Piper Sandler. They currently have a $9.00 target price on the stock, down from their previous target price of $15.00.
OptiNose (NASDAQ:OPTN) had its neutral rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $9.00 price target on the stock, down from their previous price target of $18.00.
Ouster (NYSE:OUST) had its buy rating reaffirmed by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $17.00 target price on the stock.
PDD (NASDAQ:PDD) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $160.00 target price on the stock.
Planet Labs PBC (NYSE:PL) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $6.30 target price on the stock.
Privia Health Group (NASDAQ:PRVA) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $30.00 price target on the stock.
Reddit (NYSE:RDDT) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $220.00 price target on the stock.
Skye Bioscience (NASDAQ:SKYE) had its outperform rating reaffirmed by analysts at William Blair.
Skye Bioscience (NASDAQ:SKYE) had its outperform rating reissued by analysts at William Blair.
Stryker (NYSE:SYK) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $442.00 price target on the stock.
Terns Pharmaceuticals (NASDAQ:TERN) had its market perform rating reaffirmed by analysts at William Blair.
TTM Technologies (NASDAQ:TTMI) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $33.00 price target on the stock.
Valneva (NASDAQ:VALN) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $17.00 target price on the stock.
Vor Biopharma (NYSE:VOR) had its outperform rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They currently have a $8.00 price target on the stock.
Receive News & Ratings for Adicet Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.
